Navigation Links
AEterna Zentaris' Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia
Date:4/22/2008

QUEBEC CITY, April 22 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that its partner, Spectrum Pharmaceuticals (NASDAQ: SPPI), released Phase 2b results for ozarelix, a luteinizing hormone-releasing hormone (LHRH) antagonist in benign prostatic hyperplasia (BPH).

Spectrum indicated that ozarelix demonstrated sufficient clinical activity to justify its continued development in BPH. Based on these results, Spectrum is planning to submit a protocol to the FDA for the next study of ozarelix in BPH.

"We are pleased that Spectrum is proceeding with plans for their upcoming study," stated Paul Blake, M.D., Senior Vice President and Chief Medical Officer of AEterna Zentaris. "AEterna Zentaris remains committed about the potential of LHRH antagonists for BPH, particularly for our lead candidate cetrorelix, which has produced robust and consistent findings in Phase 2 trials and is currently being evaluated in three multi-center Phase 3 trials in the United States, Canada and Europe." He said that results from the cetrorelix Phase 3 program are expected in the third quarter of 2009.

About Ozarelix and Partnerships

Ozarelix is an injectable fourth generation LHRH antagonist administered as an intramuscular injection. In August 2004, AEterna Zentaris granted Spectrum Pharmaceuticals an exclusive license to develop and market ozarelix for all potential indications in North America (inc
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia
2. AEterna Zentaris Announces Changes to its Management Team
3. AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights
4. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
5. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
6. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
7. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
8. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
9. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
10. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
11. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014  Spherix Incorporated (SPEX) -- an ... monetization of intellectual property, today announced that the Company ... June 30, 2014 on Monday, August 18, 2014 for ... a.m. ET on Monday, August 18, 2014 to discuss ... the company,s CEO, Anthony Hayes . ...
(Date:7/23/2014)... Arab Emirates (UAE) (PRWEB) July 23, 2014 ... Century recently announced that its biobanking project, ... , Ph.D. to its growing Advisory Board. Scott ... very pleased to have Dr. Vaught onboard with Provia’s ... depth and expertise that Provia’s management team brings to ...
(Date:7/23/2014)... ANGELES , July 23, 2014 /PRNewswire-iReach/ -- Think ... cognitive performance for the long term. They are the ... edge of sustained energy as an alternative to the ... Think Drinks on Indiegogo on July 29, 2014, with ... 30-day campaign. Photo - http://photos.prnewswire.com/prnh/20140723/129697 ...
(Date:7/23/2014)... julio de 2014 ADB International Group ... anunciado hoy una asociación con Austen BioInnovation Institute ... el Instituto), para el propósito de llevar el ... de señal bioeléctrica (el E-QURE BST Device), al ... tiene una importante experiencia en cicatrización de heridas, ...
Breaking Biology Technology:Spherix Schedules Shareholder Update Call 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 3Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 4truBrain Neuroscientists To Launch More Effective, Healthier Alternative To Energy Drinks On Indiegogo 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 3ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 4ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 5ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 6
... , , , ... Inc. (Nasdaq: ITMN ) today announced that it will ... help further the research of inherited genetic factors that may play ... researchers at National Jewish with access to DNA collected from patients ...
... ... announced that Henry "Pete" Linsert, Jr. has joined its Board of Directors. , ... Alachua, FL (PRWEB) September ... joined its Board of Directors., , ,Mr. Linsert is President and CEO of Columbia ...
... BETHESDA, Md., Sept. 16 American Capital Ltd. ... 15, it completed the sale of its portfolio company Axygen ... Inc., to Corning Incorporated for approximately $400 million. The ... fee income, from the equity invested by American Capital,s affiliated ...
Cached Biology Technology:InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis 2InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis 3NovaMin Technology Inc. Welcomes New Board Member 2American Capital Receives $182 Million In Proceeds From Sale of Axygen Bioscience 2American Capital Receives $182 Million In Proceeds From Sale of Axygen Bioscience 3American Capital Receives $182 Million In Proceeds From Sale of Axygen Bioscience 4
(Date:7/24/2014)... led by the University of York has carried out ... Western Indian Ocean. , The results, reported in ... revolution in the management of marine protected areas, with ... km in the region now under local community ... the seas and coasts designed to protect wildlife from ...
(Date:7/24/2014)... scientists from Singapore have developed Asia,s first genetic test ... that affects the cornea called corneal stromal dystrophy which ... , Called the POLARIS TGFBI (Transforming Growth Factor beta ... in the diagnosis and management of patients with corneal ... a TGFBI mutation who may also be at risk ...
(Date:7/23/2014)... A new study of identical twins has found that ... The study, in the journal Child Development , ... and King,s College London. , "Since reading is an ... for reading instruction," according to Stuart J. Ritchie, research ... led the study. "Early remediation of reading problems might ...
Breaking Biology News(10 mins):Western Indian Ocean communities play vital role in conservation 2Singapore team develops Asia's first genetic test that can prevent corneal blindness 2Singapore team develops Asia's first genetic test that can prevent corneal blindness 3Stronger early reading skills predict higher intelligence later 2
... a perceived danger, is a response that differs from ... scientists thought. Now researchers at Tel Aviv University are ... has implications for helping clinicians better treat victims of ... and his graduate student Rony Izhar of Tel Aviv ...
... biologists at the University of Toronto (U of T) ... determining whether a species opts for sexual over asexual ... Becks and Professor Aneil Agrawal of the Department of ... spatially heterogenous environments habitats characterized by uneven concentrations ...
... BEDFORD, Mass., Oct. 14 Aware, Inc. (Nasdaq: ... telecommunications and biometrics industries, has scheduled a conference call to ... on Thursday, October 28, 2010, at 5:00 p.m. Eastern Time. ... host the earnings conference call. This call is ...
Cached Biology News:Is anxiety contagious? 2Is anxiety contagious? 3Aware, Inc. Announces Q3'10 Earnings Conference Call 2
RECK (F-20)...
... This adapter allows ... (AB-0800 and AB-1000) PCR ... in the ABI PRISM® ... contact ABgene® for information ...
... Eliminates nonspecific products due to inactivity ... allows extension through DNA regions which contain ... an 'A' overhang ,TEMPase II is ... Polymerase that remains inactive at room ...
... solution. Cleaves a-(1-3)- and ... and glycoproteins. It is particularly efficient for ... pH must be neutral or above, for ... Unit Definition: One unit will hydrolyze ...
Biology Products: